Gabapentin 600mg 70518 2842 01
Gabapentin Tablet
Product Images NDC 70518-2842
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-2842). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Gabapentin 600mg 70518 2842 02
Gabapentin is a prescription medication produced by Ascend Labs, LLC in Montvale, NJ. It is only available with a valid prescription and should be kept away from children. The medication should be stored at a temperature between 20-26°C (63-77°F) with brief excursions to 15-30°C (59-86°F) permitted. For directions on use, refer to the package insert. The medication has been repackaged by RemedyRepack Inc. in Indiana, PA.*
Remedy_label (Remedy Label)
Gabapentin is a prescription drug manufactured by Ascend Labs, LLC and repackaged by RemedyRepack Inc. The drug is only available with a doctor's prescription and should be kept out of the reach of children. The package insert should be consulted for directions on how to use the medication. The drug should be stored between 20-26°C (63-77°F) with excursions permittedto 15-30°C (59-86°F) [See USP]. Lot number and expiration date are not available.*
Gabapentin Equation (Gabapentin Equation)
This appears to be a medical formula for calculating the estimated creatinine clearance (CLCr) using the serum creatinine levels and a coefficient of 0.85 for female patients. The result is given in milliliters per minute (mL/min). However, the characters "140 - ight" are not clear and relevant information cannot be obtained from them.*
Gabapentin Fig1
The text describes a graph with a mean pain score of 10. The graph also has two periods: a 4-week dose titration period and a 4-week fixed dose period. The graph compares the placebo group with the Gabapentin group who received 3600 mg/day. The text also includes some symbols that may have been incorrectly converted due to errors.*
Gabapentin Fig2
This appears to be a table or graph showing the mean pain score over a period of time, with different dosage levels of gabapentin and a placebo being tested. Without more context, it is not clear what the units of pain or time are, or what population was being studied.*
Gabapentin Fig3
This appears to be a chart or table with different percentages, possibly related to clinical studies on pain reduction in patients. Without further information, it is difficult to provide a more precise description.*
Gabapentin-fig4 (Gabapentin Fig4)
Gabapentin-structure (Gabapentin Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
